-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target antiemetic injection with phosphorapitamparonosetron for injection. The approved indication is “for the prevention of acute and delayed nausea and vomiting caused by moderate emetic chemotherapy (MEC) in adult patients”.
Share
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the addition of a Class 1 innovative drug independently developed by the company and China's first ultra-long-lasting original dual-target antiemetic injection with phosphorapitamparonosetron for injection. The approved indication is “for the prevention of acute and delayed nausea and vomiting caused by moderate emetic chemotherapy (MEC) in adult patients”.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending